Clinical Trial Search

Primary: Change From Baseline in Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) Physical Health Composite Summary and Mental Health Composite Summary Scores at…

Primary: Number of Male Clients Who Will Undergo Circumcision (Uptake of VMMC) — 8; 25; 13; 17 Participants — p=0.044

Primary: Number of Participants With Successful Endoluminal Treatment of Thoracic Lesion — 294 Participants

Primary: Treatment-emergent Adverse Events (TEAEs), Related TEAEs, Serious TEAEs, and Adverse Events of Special Interest (AESIs) — 6; 4; 5; 0 Participants

Primary: Necrotising Enterocolitis - for the Enteral Nutrition Comparison — NA; NA; NA; 7 Participants

Primary: Study Effectiveness for Skin Aesthetic Improvement — 1.25 score on a scale

Primary: Percentage of Donors Whose Cells Were Successfully Mobilized and Collected With a Sufficient CD34+ Cell Dose Using Plerixafor as the Mobilizing Agent, Using an…

Primary: Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy…

Primary: Stage I - Safety (Type, Frequency, Severity and Relationship of Adverse Events to Study Treatment) and Tolerability — 25 mg

Primary: Secondhand Smoke Exposure — 11.70; 12.08; 10.86; 10.51 days with SHS exposure

Primary: Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) — -3.44…

Primary: Participants That Responded to Eltrombopag — 1; 14 Participants

Primary: Questionnaire Scale "Intentions for Future Use" — 3.1; 3.7 units on a scale

Primary: Opioid Craving Using Visual Analogue Scale — 3.909; 6; 4.556; 5.5 score on a scale

Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm